Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

N/A

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03316170Phase 2Completed

Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors

Role: collaborator

NCT00596310Not ApplicableCompleted

Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

Role: collaborator

NCT02048917Phase 1Completed

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

Role: collaborator

NCT00654030Phase 2Completed

Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer

Role: collaborator

NCT00378404Phase 1Terminated

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

Role: collaborator

NCT00247416Phase 2Completed

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

Role: collaborator

All 6 trials loaded